The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
BACKGROUND
The factors predictive of the presence or the absence of esophageal varices in hepatitis C virus (HCV) and advanced fibrosis have not been defined.


OBJECTIVE
To define the prevalence of esophageal varices and the factors that are positively and negatively with such varices in hepatitis C and advanced fibrosis.


METHODS
A prospective study of esophageal varices and associated risk factors in subjects with hepatitis C and advanced fibrosis.


METHODS
Prerandomization data from the HALT-C (hepatitis C long-term antiviral treatment against cirrhosis) clinical trial.


METHODS
Subjects with bridging fibrosis or cirrhosis, who were virologic nonresponders to treatment with pegylated interferon alpha 2a and ribavirin, underwent endoscopy.


RESULTS
Sixteen percent of subjects with bridging fibrosis (95/598) and 39% of subjects with cirrhosis (164/418) had varices (P < .0001); 2% of subjects with bridging fibrosis (13/598) and 11% of those with cirrhosis (48/418) had medium or large varices. Subjects with bridging fibrosis and varices had a significantly lower platelet count and higher bilirubin and international normalized ratio (INR) compared with those without varices, suggesting that the biopsy may have underestimated the severity of fibrosis. A platelet count >150,000/mm(3) was associated with a negative predictive value of 99% for esophageal varices. By logistic regression modeling, African American race and female sex were protective, whereas a lower platelet count and higher bilirubin and INR predicted varices (c statistic, 0.758).


CONCLUSIONS
The risk of having varices increases with decreasing platelet counts, increasing bilirubin, and INR. The probability of having medium or large varices at platelet counts >150,000/mm(3) is negligible in this population.
Sanyal
Arun J
AJ
Division of Gastroenterology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
Fontana
Robert J
RJ
Di Bisceglie
Adrian M
AM
Everhart
James E
JE
Doherty
Michael C
MC
Everson
Gregory T
GT
Donovan
John A
JA
Malet
Peter F
PF
Mehta
Savant
S
Sheikh
Muhammad Y
MY
Reid
Andrea E
AE
Ghany
Marc G
MG
Gretch
David R
DR
Halt-C Trial Group
D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D018450:Disease Progression; D016099:Endoscopy, Gastrointestinal; D004932:Esophageal and Gastric Varices / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000150:complications* / Q000175:diagnosis / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
D000998:Antiviral Agents